Nuvation Bio Inc (NUVB)
NYSE:NUVB
Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$5.08
-$0.19(-5.85%)
At close: 4:00 PM EST
$5.08
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.57 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.27M
Market Cap
$1.65B
Enterprise Value$1.52B
Total Cash (Recent Filing)$533.73M
Total Debt (Recent Filing)$9.83M
Price to Earnings (P/E)69.0
Beta1.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding348,201,970
10 Day Avg. Volume4,410,022
30 Day Avg. Volume4,268,400
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.65
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda-11.00
Forecast
1Y Price Target
$13.17Price Target Upside159.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$203.16M
Bulls Say, Bears Say
Bulls Say
Clinical Development StrategyDurable Phase 2 responses for safusidenib and management's plan to pursue an accelerated regulatory pathway with a focused registration trial create prospects for quicker approval and meaningful data-driven value inflection.
Commercial UptakeIbtrozi's rapid market penetration across multiple therapy lines and an exclusive ex-U.S. licensing deal with a major partner indicate stronger commercial traction and recurring revenue potential.
Regulatory ApprovalEMA validation of the marketing application for taletrectinib, supported by pooled pivotal trial data and favorable rapporteur feedback, advances the filing toward potential EU approval and associated milestone payments.
Bears Say
Clinical RiskNegative proof-of-concept results for any pipeline candidate could materially weaken the company's outlook by undermining approval prospects and investor confidence.
Financial And Governance RiskPotential dilution from future financing needs, along with conflicts of interest in some research coverage, could undermine investor confidence and cloud valuation clarity.
Product Adoption RiskHigh treatment discontinuation linked to patients starting Ibtrozi in later therapy lines, combined with intense competition, could suppress sales momentum and slow broader adoption.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $1.57 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $1.65B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 72 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on May 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.038.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.15.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 348,201,970 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.17 (159.19% Upside)
$13.17 (159.19% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
109.77%
12-Months-Change
Fundamentals
Return on Equity
-44.10%
Trailing 12-Months
Asset Growth
23.91%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum for Iptrozy: robust physician awareness (97%), growing first‑line mix (>50% of new starts), meaningful sequential product revenue growth (18% QoQ to $18.5M), and differentiated durability and CNS efficacy (50‑month PFS/DOR in TKI‑naive; 66% intracranial RR). Financially, the quarter was bolstered by a near‑term collaboration upfront (~$60M) and a healthy cash position ($533.7M) with $50M credit available. Key challenges include a steady absolute level of new patient starts (~200/quarter), testing shortfalls in the community (<50% in some centers) that limit incidence capture, upward pressure on gross‑to‑net (targeting stabilization in the high‑20s to ~30%), and sizeable operating expenses ($73.5M). Overall, positive clinical differentiation, market access progress, partnerships, and balance sheet strength outweigh the operational and market access headwinds.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$13.17
▲(159.19% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.59% Insiders
15.94% Mutual Funds
20.37% Other Institutional Investors
29.19% Public Companies and
Individual Investors